Do you have a loved one with agitation associated with Alzheimer’s dementia?

Is their agitation becoming overwhelming?

Is someone you care for with Alzheimer's dementia exhibiting excessive motor activity, verbal and/or physical aggression?

If so, they may qualify for the ASPECT™ clinical research study. The purpose of this study is to evaluate the safety and effectiveness of an investigational drug for agitation associated with Alzheimer’s dementia.  

The ASPECT study can help us learn more about a potential treatment for agitation in patients with Alzheimer’s dementia.

A clinical research study for agitation associated with Alzheimer’s dementia
Depressed senior woman at home feeling sad.

To be eligible for this study, a potential participant must:

  • Be between the ages of 50 and 90

  • Have a diagnosis of probable Alzheimer’s dementia

  • Have moderate-to-severe agitation that interferes with their daily life

  • Have a reliable caregiver who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures

Other eligibility criteria will apply.

If you are caring for someone with moderate-to-severe agitation associated with Alzheimer’s dementia, see if they are eligible to participate in the ASPECT™ clinical research study.

Those who qualify will receive study-required medical care and study drug at no cost.

Play Video

About Agitation associated with Alzheimer’s Dementia

Alzheimer’s Dementia (AD) is a progressive neurodegenerative disease. 3
Agitation is widely recognized by clinicians as a common and important clinical feature of Alzheimer’s dementia. Symptoms of agitation place a serious burden on the individuals with Alzheimer’s dementia and their caregivers, significantly affecting their health-related quality of life for all concerned. 5
Over the course of the disease, many patients with Alzheimer’s dementia will likely experience agitation. 4
Agitation has also been associated with increased risk of institutionalization and earlier progression to severe dementia. 2,6,7
Agitation is characterized by excessive motor activity, verbal aggression, and physical aggression that causes emotional distress to the patient. 1

These are just some of the many reasons why more research on the disease is needed.

Sources:
1 Cummings J, et al. “Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.” International Psychogeriatrics, 27:1, 7–17. 2015. https://www.ncbi.nlm.nih.gov/pubmed/25311499
2 Knapp M, et al. “Predictors of care home and hospital admissions and their costs for older people with Alzheimer’s disease: findings from a large London case register.” BMJ Open, 6:11, 1-15. 2016. https://bmjopen.bmj.com/content/bmjopen/6/11/e013591.full.pdf
3 DeTure MA, et al. The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration. 2019;14:32;doi.org/10.1186/s13024-019-0333-5
4 Alzheimer’s Association. “2017 Alzheimer’s Disease Facts and Figures.” Alzheimer’s & Dementia, 13: 325-373. April 2017. https://www.sciencedirect.com/science/article/pii/S1552526017300511?viewFullText=true
5 Laybourne A, et al. “Carer coping and resident agitation as predictors of quality of life in care home residents living with dementia: Managing Agitation and Raising Quality of Life (MARQUE) English national care home prospective cohort study.” International Journal Of Geriatric. Psychiatry, 34:106-113. 2018. https://www.ncbi.nlm.nih.gov/pubmed/30276865
6 Rabins P, et al. “Neuropsychiatric symptoms at baseline predict shorter time to severe dementia in a population-based sample of incident Alzheimer’s disease: The Cache County dementia progression study.” Alzheimer’s and Dementia, supplement, 8.4: 126-127. 2012. https://www.alzheimersanddementia.com/article/S1552-5260(12)00465-7/abstract
7 Peters M, et al. “Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study.”172(5): 460-5. 2015. https://www.ncbi.nlm.nih.gov/pubmed/25585033.

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience.  Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.